ClinicalTrials.gg
RecruitingNCT05145361Updated May 5, 2026

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

An Early Phase 1 interventional study of B001 injection and Placebo in NMO Spectrum Disorder, sponsored by Shanghai Pharmaceuticals Holding Co., Ltd. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Shanghai Pharmaceuticals Holding Co., Ltd · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 72 studies in Neuromyelitis Optica with a site in China — 37 open to participants now, 43 under way, 7 of them phase 3. Neuromyelitis Optica · China.

Planned enrollment
18th of 51
45 · median 23
Started
2022
with 10 others
Phase 1
17 of 72
10 open now
Primary completion
2026-12
later than 12 of 42 live
Registered
20th of 72
by date

Among the 72 studies in Neuromyelitis Optica with a site in China, this one is the 18th largest by planned enrollment of the 51 interventional ones that give a count, is one of 11 that started in 2022, is one of 17 in phase 1, reaches primary completion later than 12 of the 42 other live ones, and was the 20th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

37 of the 72 studies in Neuromyelitis Optica with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Neuromyelitis Optica with a site in China, or all of them as a file.
02

Study summary

The objectives of this phase Ib study are to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenic profiles of B001 in subjects with aquaporin-4 antibody (AQP4-IgG) positive NMOSD.

03

Conditions studied

  • NMO Spectrum Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. NMOSD as defined by either of the following 2015 criteria with anti-AQP4 antibody (Ab) seropositive status at screening
  2. Clinical evidence of at least 1 documented relapse in last 12 months prior to screening
  3. Expanded Disability Status Scale (EDSS) score from 0 to 7.5 inclusive at screening
  4. Age 18 to 70 years, inclusive at the time of

Exclusion criteria

Exclusion Criteria:

  1. Any previous treatment with anti-CD20, eculizumab, anti-BLyS monoclonal antibody (e.g., belimumab), any other treatment for prevention of multiple sclerosis (MS) relapse (e.g., interferon, natalizumab, glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate) within 6 months prior to baseline.
  2. Received such as azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide, tacrolimus, mitoxantrone, cyclosporine A, etc, and rug therapy, biological agents such as satralizumab, tocilizumab, eculizumab, etc, 3 months prior to the first administration.
  3. Evidence of serious uncontrolled concomitant diseases that may preclude participant participation, as described; Other nervous system disease, cardiovascular disease, hematologic/hematopoiesis disease, respiratory disease, muscular disease, endocrine disease, renal/urologic disease, digestive system disease, congenital or acquired severe immunodeficiency.
  4. Known active infection within 3 months prior to baseline
  5. Pregnancy or lactation.
  6. History of severe allergic reaction to a biologic agent
  7. Evidence of chronic active or C
  8. Evidence of active tuberculosis
  9. Following laboratory abnormalities at screening*:

    1. White blood cells (WBC) \<4.0 x10\^3/microliter (μL)
    2. (ANC)
    3. Absolute lymphocyte count \<0.5 x10\^3/μL
    4. count \<80 x 10\^9/ L
    5. (AST) or alanine aminotransferase
  10. History of drug or alcohol abuse within 6 months prior to baseline
  11. Receipt of any live or within 4 weeks prior to baseline
  12. Uncontrolled systemic diseases, including hypertension that cannot be effectively controlled after treatment (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg), diabetes, gastrointestinal diseases, etc.; or the investigator believes that there is anything inappropriate reasons for selection.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    B001 injection

    Subjects randomized to this arm will receive B001 twice, at day 1 and day 15, up to the end of the study.

    Drug: B001 injection

  • Placebo comparator
    Placebo

    Subjects randomized to this arm will receive Placebo twice, at day 1 and day 15, up to the end of the study.

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Measurement of DLT in all subjects.

    Time frame: Up to 18 days.

  2. Evaluate incidence of treatment-emergent adverse events [Safety and Tolerability].

    Time frame: Up to 1 year

Secondary outcomes

  1. Maximum serum concentration (Cmax) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  2. Time of maximum serum concentration (Tmax) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  3. Area under the serum concentration-time curve (AUC) of the Dosing Interval (0-14D) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  4. Area under the serum concentration-time curve (AUC) of the Dosing Interval (0-Last) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  5. Area under the serum concentration-time curve (AUC) of the Dosing Interval (0-infinity) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  6. Accumulation ratio of maximum serum concentration (Rac_Cmax) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  7. Accumulation ratio of area under the serum concentration-time curve (Rac_AUC) of the Dosing Interval (0-14D) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  8. Terminal rate constant(λz) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  9. Half-life (t1/2) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  10. Total clearance(CL) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  11. Volume of distribution(Vz) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  12. Percentage of area under the serum concentration-time curve (AUC 0-infinity) obtained by extrapolation (%AUCex) of B001.

    To characterize the PK (Pharmacokinetics) of B001.

    Time frame: Through study completion, up to 2 years

  13. Percentage of subjects with ADA to B001 and neutralizing resistance (Nab)

    Time frame: Through study completion, up to 2 years

  14. Time to First Protocol-Defined Relapse (TFR) in the Double-Blind Period

    Time frame: Through study completion, up to 2 years

  15. Change in Expanded Disability Status Scale (EDSS) Score

    The EDSS provides a total score on a scale that ranges from 0 to 10 in 0.5 increments that represent higher levels of disability. Increasing disability is reflected in an increasing EDSS score.

    Time frame: Through study completion, up to 2 years

  16. Time to EDSS Worsening

    Time frame: Through study completion, up to 2 years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Jia D, Wang H, Jiang W, Shen Y, Guo J, Zhao D, Zhang M, Meng H, Xue H, Song Y, Yao Q, Xie N, Zhang C. A novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trial. Front Immunol. 2026 Apr 16;17:1676908. doi: 10.3389/fimmu.2026.1676908. eCollection 2026. PubMed 42079612 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Dec 2026, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2021
First posted
Dec 6, 2021
StartActual
Apr 7, 2022
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05145361
Responsible party
Sponsor
First posted
Dec 6, 2021
Start date
Apr 7, 2022
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Fu-Dong Shi, MD,PhD
Contact
Shifudong219@163.com
022-60814587
Fu-Dong Shi, MD,PhD
principal investigator · Tianjin Medical University General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tambotatug · Anti-CD20 Monoclonal Antibody B001

Start the discussion